Isoniazid: metabolic aspects and toxicological correlates.
about
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2Isoniazid metabolism and hepatotoxicityIn vitro antioxidant, antibacterial, and cytotoxic activity and in vivo effect of Syngonium podophyllum and Eichhornia crassipes leaf extracts on isoniazid induced oxidative stress and hepatic markersMetabolomics of urine for the assessment of microvesicular lipid accumulation in the liver following isoniazid exposureProtective effects of metallothionein on isoniazid and rifampicin-induced hepatotoxicity in mice.A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteersQSAR based therapeutic management of M. tuberculosis.Isoniazid-induced severe hepatotoxicity: an infrequent but preventable cause of liver failure in children treated for latent tuberculosis infection.Tau as a therapeutic target in neurodegenerative disease.A metabolic biosignature of early response to anti-tuberculosis treatment.Role of CYP3A in isoniazid metabolism in vivoMechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.Isoniazid: A Review of Characteristics, Properties and Analytical Methods.Neuropsychiatric Effects of Antimicrobial Agents.A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?PharmGKB summary: isoniazid pathway, pharmacokinetics.NAT2 Genotype and Isoniazid Medication in Children.Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.Synthesis, characterization and in-vitro antitubercular activity of isoniazid-gelatin conjugate.From the Cover: Developmental Neurotoxicants Disrupt Activity in Cortical Networks on Microelectrode Arrays: Results of Screening 86 Compounds During Neural Network Formation.Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study.Deficiency of N-acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver.Investigations on the Influence of Zidovudine in the Pharmacokinetics of Isoniazid and Its Hepatotoxic Metabolites in Rats.Lipopolysaccharide exposure augments isoniazide-induced liver injury.Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.NMR signal enhancement by effective SABRE labeling of oligopeptides.NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in Mycobacterium tuberculosis?
P2860
Q27011622-1B0C12A7-00D6-447F-BAE6-F50BC9EF7098Q28076859-D547AE72-147C-4294-914C-6CD175658940Q34064597-FA9F66EC-C387-407E-9FAD-877256B91390Q34262365-B12088B9-378A-4E33-9CD8-92EEC4AE52A8Q34964833-EF2C30C7-E5B3-446B-8A3A-66C3361424EDQ35666603-A1851D5C-82D3-4194-9986-90EDC7A3FEC5Q36097299-0420C47E-FB5A-42BA-B3C7-E85D11BE6C12Q36158322-997D2EAB-AA81-405F-BB0D-F2ABE763B8D4Q36359056-2DA6D634-A9CD-4505-A480-253ACAA2D9DDQ36885262-B7BD4882-177F-4846-9C00-B396A8871894Q36970350-201F2002-DE0A-4262-8AD0-64728004EACEQ37569320-2D34A1D8-1CE5-49CE-8860-9457AC791F26Q37732312-0BBB0235-00EC-4849-A05C-39C34F9D090EQ38208324-396555A4-8A24-4A24-90C4-21C5A0F6D675Q38803026-EB2A242D-1D8F-4604-9557-843D27704968Q38851516-169DADE1-F9EB-455D-872D-BCABED065ADCQ39083469-337D671A-1441-4D11-B705-9EF802AE9433Q39135986-1D6F606A-7B2B-4748-A889-92B0EF414B49Q40592548-A5E1DBDE-0C20-47FE-B4DF-3580B4949EB6Q41875502-AFDD7A56-74D6-4764-8596-607698538EF2Q42090708-C611BA7F-CDB1-490E-9449-6E0183F0E9B4Q42387608-33AF7AEA-DAF8-4B54-9CC6-B6D20D0B0FFCQ42696912-7C59316C-61D9-4DDE-A030-7F025B0BC271Q42719407-23F192E4-272D-47D0-B4B4-8E425E9F9EF4Q45945253-48413911-1A33-4B47-8231-AF4BA2E793E7Q47221266-CD666DB1-7234-4D71-9372-022BA7A29659Q47828041-4FAAAF63-7E10-4451-95B2-4BA61E8991FAQ50090481-BA69C155-7D45-4C2F-97D8-95BF011364CAQ52654492-3B0B9AF7-A972-474E-AC24-7CA25FCC037AQ52742072-8E4462F4-0BCF-4861-8C55-65B4ECDE7C93Q53418905-FA94F409-6F9E-4580-A841-D4BE713D8904Q54314510-B43F6F08-2B2B-4215-8AAB-4E5024E8FCC2Q55333929-EEDD5CC3-C06E-46D9-9DD5-B3A8BAB87B09
P2860
Isoniazid: metabolic aspects and toxicological correlates.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Isoniazid: metabolic aspects and toxicological correlates.
@en
Isoniazid: metabolic aspects and toxicological correlates.
@nl
type
label
Isoniazid: metabolic aspects and toxicological correlates.
@en
Isoniazid: metabolic aspects and toxicological correlates.
@nl
prefLabel
Isoniazid: metabolic aspects and toxicological correlates.
@en
Isoniazid: metabolic aspects and toxicological correlates.
@nl
P1476
Isoniazid: metabolic aspects and toxicological correlates.
@en
P2093
Paolo Preziosi
P304
P356
10.2174/138920007782798216
P407
P577
2007-12-01T00:00:00Z